Spire Healthcare Group (LON:SPI) Rating Lowered to “Sector Perform” at Royal Bank Of Canada

Spire Healthcare Group (LON:SPI) was downgraded by analysts at Royal Bank Of Canada to a “sector perform” rating in a research note issued on Monday, London Stock Exchange reports. They currently have a GBX 250 price objective on the stock, down from their prior price objective of GBX 300. Royal Bank Of Canada’s target price indicates a potential upside of 1.83% from the company’s current price.

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a GBX 245 price objective on shares of Spire Healthcare Group in a research note on Friday, May 15th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of GBX 247.50.

Spire Healthcare Group Price Performance

Shares of LON:SPI opened at GBX 245.50 on Monday. The stock has a market cap of £983.47 million, a PE ratio of 61.38, a PEG ratio of 1.06 and a beta of 0.93. The company’s fifty day moving average is GBX 228.69 and its 200 day moving average is GBX 201.50. Spire Healthcare Group has a 52 week low of GBX 140.80 and a 52 week high of GBX 256.50. The company has a quick ratio of 0.73, a current ratio of 0.63 and a debt-to-equity ratio of 177.14.

Key Stories Impacting Spire Healthcare Group

Here are the key news stories impacting Spire Healthcare Group this week:

• Positive Sentiment: Recommended cash offer provides a clear valuation catalyst. Spire has agreed to the offer from Tulip UK Bidco, backed by a Toscafund-led private-equity consortium. The all-cash transaction gives shareholders a defined exit value and is the main reason the stock is rising. Spire Healthcare agrees to £1.03bn takeover
• Positive Sentiment: Deal marks a substantial premium opportunity versus the pre-announcement valuation. The proposed £1.03 billion enterprise value is close to or above Spire’s recent equity-market valuation, supporting the view that shareholders are receiving an attractive offer and reducing near-term standalone execution risk. Spire Healthcare accepts GBP1 billion takeover offer
• Neutral Sentiment: Management and board changes accompany the transaction. Spire named David Sloman interim chief executive and announced a board overhaul as it proceeds with the takeover. The changes may help facilitate the deal, although they add transition risk until completion. Spire Healthcare names David Sloman interim CEO
• Negative Sentiment: Shareholders remain exposed to deal-completion risk. The takeover must still satisfy customary conditions and proceed through the required approval process. Any delay, competing bid or failure to complete could cause the shares to fall back toward their pre-offer level. The transaction also removes Spire from the public markets, limiting future upside for investors who do not participate in the cash exit. UK private hospital firm agrees takeover

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments. The company also provides eye surgery and treatments, family planning, gastroenterology, general medicine, general surgery, haematology, hand surgery, hip and knee treatment, and heart and kidney treatments.